Marathon Capital Management
MDCX icon

Marathon Capital Management’s Medicus Pharma MDCX Stock Holding History

Marathon Capital Management’s Portfolio MDCX Stock Details MDCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-310
Closed -$6.92K – 195
2026
Q2 		$6.92K Hold
310
– – ﹤0.01% 186
2026
Q1 		$7.12K Buy
+310
New +$16.2K ﹤0.01% 170

Other funds holding MDCX

Interchange Capital Partners
Interchange Capital Partners Pittsburgh, Pennsylvania $598M AUM 31.79% 1-Year Est. Return
Sterling Investment Advisors (Pennsylvania)
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $606M AUM 21.78% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
May Hill Capital
May Hill Capital Cohasset, Massachusetts $510M AUM 23.75% 1-Year Est. Return
Wilmington Savings Fund Society
Wilmington Savings Fund Society Wilmington, Delaware $4.39B AUM 17.99% 1-Year Est. Return
Summit Global Investments
Summit Global Investments Bountiful, Utah $2.02B AUM 17.87% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
STALEY CAPITAL ADVISERS
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.67B AUM 20.47% 1-Year Est. Return

Marathon Capital Management's MDCX Position: Q3 2026 in Review

Marathon Capital Management sold out of Medicus Pharma (MDCX) in Q3 2026, closing a stake of 310 shares — an estimated $6.92K sold.

Marathon Capital Management first reported a position in MDCX in Q1 2026 and held it in 2 quarters. The position peaked at $7.12K in Q1 2026. 10 funds tracked by Wall St. Rank hold MDCX as of Q3 2026.

  • Marathon Capital Management reported no remaining Medicus Pharma position as of Q3 2026 after selling out during the quarter.
  • Marathon Capital Management sold 310 Medicus Pharma shares in Q3 2026, an estimated $6.92K.
  • Marathon Capital Management first reported a position in Medicus Pharma in Q1 2026 and held it in 2 quarters.
  • Marathon Capital Management's Medicus Pharma position peaked at $7.12K in Q1 2026.
  • 10 funds tracked by Wall St. Rank held Medicus Pharma as of Q3 2026.

Based on Marathon Capital Management's 13F filing for Q3 2026, filed 23 Oct 2026.